ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013680" target="_blank" >RIV/00023736:_____/24:00013680 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11310/24:10486192 RIV/00216208:11320/24:10486192

Výsledek na webu

<a href="https://doi.org/10.1152/ajpcell.00188.2024" target="_blank" >https://doi.org/10.1152/ajpcell.00188.2024</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1152/ajpcell.00188.2024" target="_blank" >10.1152/ajpcell.00188.2024</a>

Jazyk výsledku

angličtina

Název v původním jazyce

ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells

Popis výsledku v původním jazyce

Clinical experience with tyrosine kinase inhibitors (TKIs) over the past two decades has shown that, despite the apparent therapeutic benefit, nearly 30% of patients with chronic myelogenous leukemia (CML) display primary resistance or intolerance to TKIs, and approximately 25% of those treated are forced to switch TKIs at least once during therapy due to acquired resistance. Safe and effective treatment modalities targeting leukemic clones that escape TKI therapy could hence be game changers in the professional management of these patients. Here, we aimed to investigate the efficacy of a novel therapeutic oligonucleotide of unconventional design, called ASP210, to reduce BCR-ABL1 mRNA levels in TKI-resistant CML cells, with the assumption of inducing their apoptosis.

Název v anglickém jazyce

ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells

Popis výsledku anglicky

Clinical experience with tyrosine kinase inhibitors (TKIs) over the past two decades has shown that, despite the apparent therapeutic benefit, nearly 30% of patients with chronic myelogenous leukemia (CML) display primary resistance or intolerance to TKIs, and approximately 25% of those treated are forced to switch TKIs at least once during therapy due to acquired resistance. Safe and effective treatment modalities targeting leukemic clones that escape TKI therapy could hence be game changers in the professional management of these patients. Here, we aimed to investigate the efficacy of a novel therapeutic oligonucleotide of unconventional design, called ASP210, to reduce BCR-ABL1 mRNA levels in TKI-resistant CML cells, with the assumption of inducing their apoptosis.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

American journal of physiology-cell physiology

ISSN

0363-6143

e-ISSN

—

Svazek periodika

327

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

"C184"-"C192"

Kód UT WoS článku

001271435400002

EID výsledku v databázi Scopus

2-s2.0-85198124620